Keith Michael Gottesdiener

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
New York, NY
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Mark A. Wilson, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Keith Michael Gottesdiener

Form 4 holding Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
2,310,837
Estimated value
$14,442,731
Report date
08 Oct 2024
Price
$6.25
Ownership
Direct
Form 4 holding Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
682,259
Estimated value
$4,264,119
Report date
08 Oct 2024
Price
$6.25
Ownership
By Trust
Form 4 holding Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director

Prime Medicine, Inc.

Security class
Common Stock
Shares / value
50,241
Estimated value
$314,006
Report date
08 Oct 2024
Price
$6.25
Ownership
By Spouse
Form 4 holding Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director

Prime Medicine, Inc.

Security class
Stock Option (right to buy)
Shares / value
300,000
Estimated value
Report date
08 May 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Septerna, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
11,260
Estimated value
Report date
26 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

INTERCEPT PHARMACEUTICALS, INC.

Security class
Option to Purchase Common Stock
Shares / value
0
Estimated value
Report date
08 Nov 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Keith Michael Gottesdiener

4 PRME

Prime Medicine, Inc.

Report period
08 May 2025
Transactions
1
Transaction value
$0
Accepted by SEC
12 May 2025, 16:50
Role
Exhibit 24 - Power of Attorney; Title: President and Chief Executive Officer, Director
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .